Alembic Pharma receives USFDA approval for Azelastine Hydrochloride

usfda

Alembic Pharmaceuticals has received USFDA approval for Azelastine Hydrochloride Ophthalmic Solution used for the treatment of allergic conjunctivitis. The drug is equivalent of Optivar Ophthalmic Solution of Mylan Specialty L P. According to market estimates, Azelastine Hydrochloride Ophthalmic Solution, 0.05 per cent, has an estimated market size of $8.5 million for 12 months ending December 2018.

Company Profile : Alembic Pharmaceuticals Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*